<SEC-DOCUMENT>0001628279-25-000161.txt : 20251211
<SEC-HEADER>0001628279-25-000161.hdr.sgml : 20251211
<ACCEPTANCE-DATETIME>20250326211646
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001628279-25-000161
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Heartflow, Inc.
		CENTRAL INDEX KEY:			0001464521
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				260506743
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		331 E EVELYN AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041
		BUSINESS PHONE:		650-241-1221

	MAIL ADDRESS:	
		STREET 1:		331 E EVELYN AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardiovascular Simulation, Inc.
		DATE OF NAME CHANGE:	20090519
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i74abe572e95e4a4ea41ee433ddfb5e21_1"></div><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.612%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">O&#8217;Melveny &#38; Myers LLP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Two Embarcadero Center</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28&#7511;&#688; Floor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">San Francisco, CA 94111-3823</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">T&#58; +1 415 984 8700</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">F&#58; +1 415 984 8701</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">omm.com</font></div></td></tr></table></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 26, 2025</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">VIA EDGAR</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">United States Securities and Exchange Commission</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Division of Corporation Finance</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Office of Industrial Applications and Services</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100 F Street, N.E.</font></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Attention&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Tracey Houser</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Terence O'Brien</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Juan Grana</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Katherine Bagley</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Re&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Heartflow, Inc.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Draft Registration Statement on Form S-1</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Submitted February 6, 2025</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">CIK No. 0001464521</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the addressees set forth above&#58;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On behalf of our client, Heartflow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), we hereby submit to the staff (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Staff</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) this letter setting forth the Company&#8217;s responses to the comments contained in the Staff&#8217;s letter dated March 5, 2025, regarding the above-referenced Draft Registration Statement on Form S-1, as confidentially submitted via EDGAR to the Commission on February 6, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Draft Registration Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Concurrently with the submission of this letter, the Company is confidentially submitting its revised registration statement on Form S-1 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revised Registration Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and certain exhibits via EDGAR to the Commission for review.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the Staff&#8217;s convenience, we have reproduced below the comments from the Staff in bold italics, in each case followed by the Company&#8217;s corresponding response. Where applicable, we have included references to pages in the Revised Registration Statement where the language addressing a particular comment appears. Capitalized terms used in this letter and not otherwise defined herein have the meanings ascribed to them in the Revised Registration Statement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.014em;line-height:139%">Austin  &#8226;  Century City  &#8226;  Dallas  &#8226;  Houston  &#8226;  Los Angeles  &#8226;  Newport Beach  &#8226;  New York  &#8226;  San Francisco  &#8226;  Silicon Valley  &#8226;  Washington, DC</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.014em;line-height:139%">Beijing  &#8226;  Brussels  &#8226;  Hong Kong  &#8226;  London  &#8226;  Seoul  &#8226;  Shanghai  &#8226;  Singapore  &#8226;  Tokyo</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cover Page</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure on page 62 that, after this offering, certain of your executive officers, directors, owners of more than 5% of your capital stock, and their affiliates will have the ability to influence you through their ownership position, including the potential ability to determine all matters requiring stockholder approval. Please revise your cover page to include disclosure describing the control of these shareholders and affiliates.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on the cover page.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prospectus Summary, page 1</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Here and throughout your registration statement where you provide disclosure regarding the industry in which you operate, your competitors, and market statistics, please provide support for your disclosures, including, as applicable, the basis for management's opinions or beliefs. For example only, we note the following statements&#58;</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;We estimate that there were approximately 9.5 million non-invasive tests (&#8220;NITs&#8221;) in the United States in 2023 for patients experiencing stable or acute chest pain, which we refer to as symptomatic CAD patients&#59;&#8221;</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stress-based NITs are &#8220;inaccurate, a majority of the time, and often result in either missed CAD diagnoses or unnecessary invasive procedures&#59;&#8221; &#8220;approximately 20- 50% of patients who undergo stress-based NITs go home with false negative or undetected CAD&#59;&#8221; and &#8220;up to 55% of patients receive false positives&#59;&#8221; </font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;We estimate that as of December 31, 2023, there were approximately 2,700 hospitals and outpatient facilities in the United States that perform CCTA, and this target account base has grown at a 10% CAGR from 2018 to 2023&#59;&#8221; and</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;With the elevation of CCTA to a Class 1, Level A guideline recommendation by the AHA and ACC guidelines in 2021, CCTA test volumes have grown at a 22% CAGR from 2018 to 2023 while SPECT volumes have grown at a 2% CAGR over the same time period.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please make conforming changes throughout your filing, including to your description of your business, competition, and the industry in which you operate.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 1, 3-6, 98-100, 102, 104, 107-109 and 126.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Overview, page&#160;1</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure on page 2 that &#8220;Heartflow FFRCT Analysis calculates blood flow and pinpoints functionally significant CAD at every point in the major </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">coronary arteries, guiding decisions on whether a patient requires invasive revascularization.&#8221; Please define &#8220;functionally significant.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 2, 8, 82, 99, 113 and 114.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure on page 3 that &#8220;&#91;t&#93;he CCTA + Heartflow FFRCT Analysis pathway is supported by the American Heart Association (&#8220;AHA&#8221;) and American College of Cardiology (&#8220;ACC&#8221;) guidelines, with CCTA identified as a Class 1, Level A test and Heartflow FFRCT Analysis identified as a Class 2a, Level B test,&#8221; &#8220;Heartflow FFRCT Analysis is reimbursed under a dedicated Category 1 Current Procedural Terminology (&#8220;CPT&#8221;) code,&#8221; and &#8220;A Category 1 CPT code was also recently established for Heartflow Plaque Analysis, which will take effect in January 2026, and it is covered by all seven Medicare administrative contractor (&#8220;MACs&#8221;).&#8221; Please revise your disclosure here or provide a cross reference to more detailed disclosure in the filing to further explain the various classes, levels and reimbursement categories pursuant to current clinical guidelines and reimbursement policies, including those of the AHA and ACC. We also note your disclosure on page 103 that &#8220;CCTA now has guideline support from the European Society of Cardiology Clinical Practice guidelines on Chronic Coronary Syndromes (1B), is included in the National Institute for Health and Care Excellence (&#8220;NICE&#8221;) guidelines in the United Kingdom, and in the Japanese Circulation Society (&#8220;JCS&#8221;) 2022 Guidelines in Japan.&#8221; Please revise to discuss the significance of receiving guideline support from each of these institutions.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 4, 100, 101 and 107.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure on page 22 that the Heartflow Platform relies on a CCTA first being performed, and that companies performing CCTA could determine to develop, partner with, or acquire and offer a product that competes with the Heartflow Platform, or manufacture CT scanners that are no longer compatible with the Heartflow Platform. Please revise your summary to discuss the Heartflow Platform's reliance on third-party CCTAs and compatible CT scanners, including any risks or limitations related to this reliance.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 5, 25 and 107.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please revise to disclose your accumulated deficit for the fiscal years ended December 31, 2024 and 2023.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 4, 20, 83, 101 and F-7.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Our symptomatic CAD market opportunity, page&#160;5</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note that you discuss estimates for your market opportunity in the United States throughout your filing. Please address the following issues related to your market opportunity estimates&#58;</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">You disclose on page 2 that you estimate your current market opportunity in the United States is approximately $5 billion, and that you believe &#8220;Heartflow FFRCT Analysis is applicable to approximately 33% of NIT patients annually and the majority of patients experiencing acute chest pain, which represents 3.1 million patients and an estimated market opportunity of approximately $3.3 billion in the United States.&#8221; Please provide support for your statements regarding the number of patients &#8220;experiencing acute chest pain,&#8221; including sources for this information and clarify how you arrived at a market opportunity of $3.3 billion based on this estimate. Include a discussion of the material assumptions underlying your estimates, including price per product, reimbursement rates, etc.</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">As a related matter, we note your disclosure on page 5 that &#8220;Heartflow FFRCT Analysis is reimbursed for use on any CCTA showing 40% to 90% stenosis, which &#91;you&#93; estimate to be approximately 33% of all CCTAs annually,&#8221; and that you &#8220;believe that CCTA + Heartflow FFRCT Analysis therefore is applicable to 33% of the NIT market and a majority of patients experiencing acute chest pain, which represents 3.1 million patients and an estimated market opportunity of approximately $3.3 billion in the United States.&#8221; Please provide the data, sources, and assumptions underlying your estimates of stenosis, patients, and market opportunity and explain how you calculated an estimated market opportunity in the US of approximately $3.3 billion based on these estimates. Please also clarify whether your estimated market opportunity is based on patients with a CCTA showing 40% to 90% stenosis, or &#8220;a majority of patients experiencing acute chest pain.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">You disclose that &#8220;&#91;w&#93;e believe our Heartflow Plaque Analysis is applicable to approximately 60% of NIT patients annually and the majority of patients experiencing acute chest pain, which represents 5.5 million patients and an estimated market opportunity of an incremental approximately $1.7 billion in the United States.&#8221; Please provide the data and assumptions supporting your estimates related to the proportion of NIT patients and number of patients disclosed. In addition, please discuss how your &#8220;limited market education efforts&#8221; for Heartflow Plaque Analysis impact your market opportunity estimates for this product.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 3, 6, 99-100, and 110.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that your current focus is on the United States but that you &#8220;also have a commercial presence and regulatory approval in certain international markets, including the United Kingdom, European Union and Japan, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">which &#91;you&#93; estimate represents an additional 4.2 million potential CCTA patients.&#8221; Please provide relevant sources, data, and assumptions supporting your estimate of the potential CCTA patients in these international markets.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 6, 106 and 110.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">The Offering, page&#160;12</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;i&#93;n connection with the completion of this offering, &#91;you&#93; are obligated to use certain of the net proceeds from this offering to repay $50.0 million (or $55.0 million if the underwriters exercise their option to purchase additional shares of common stock) of the indebtedness outstanding under the amended credit agreement and guaranty (the &#8220;2024 Credit Agreement&#8221;) with Hayfin Services, LLP (&#8220;Hayfin&#8221;) and to pay...fees in connection therewith.&#8221; Please revise to briefly discuss your relationship to Hayfin, including the percentage of your beneficial ownership held by entities affiliated with Hayfin.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 14, 72 and 164.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please revise your disclosure to describe the lock-up agreements discussed on pages 63 and 179 of your registration statement.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page 15.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Summary consolidated financial data, page 15</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please expand your statement of operations and balance sheet pro forma presentations to include an adjustment for the stock-based compensation expense for the restricted stock unit that will be granted concurrently with the offering as disclosed on page 13, along with disclosures that disclose the material terms of the grant, the total amount of compensation expense to be recognized, the period over which the expense will be recognized, and the assumptions used to estimate the compensation expense. Refer to Article 11-02(a)(8) of Regulation S-X for guidance. Please address this comment for all of your pro forma presentations.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 17-19. The Company respectfully advises the Staff that the restricted stock unit grant will not affect the Company&#8217;s balance sheet or capitalization at the date of the offering. The Company&#8217;s revised disclosure includes discussion that the restricted stock units will be settled in shares of common stock and vest over four years in annual equal increments, subject to continued service, on the anniversary of the grant date. </font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please expand your statement of operations pro forma presentation to include an adjustment for the interest expense and change in fair value of derivative liability, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">if any, associated with the $50 million repayment for the 2024 Credit Agreement. Please address this comment for all of your pro forma presentations.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that as a result of the refinancing of the term loans under the original 2021 credit agreement with Hayfin in connection with entering into a new Credit Agreement with Hayfin on June 14, 2024 (the &#8220;2024 Term Loan Refinancing&#8221;), the prepayment features of the Term Loan, default put option and default interest adjustment features which were determined to be embedded derivatives and requiring bifurcation and separate accounting for at fair value as a single compound derivative were eliminated. As disclosed in the fiscal year 2024 consolidated financial statements, in connection with the 2024 Term Loan Refinancing, the associated current fair value of the derivative liability of $1.1 million as remeasured at the date of the 2024 Term Loan Refinancing was derecognized and recorded as a debt discount to the 2024 Term Loan. We have therefore not included in our pro forma presentations.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">To date we have derived a significant amount of our revenue from a small number of customers, and face risks associated with a more&#8230;, page&#160;21</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;although &#91;y&#93;our Heartflow Platform had an installed base of over 1,100 accounts in the United States as of December 31, 2024, the decision-making function for many of these accounts is concentrated in a relatively small number of customers, such that the loss of one customer could result in a disproportionate loss across &#91;y&#93;our accounts.&#8221; We also note your disclosure on page 82 that &#8220;&#91;n&#93;o single customer accounted for 10% or more of &#91;y&#93;our revenue during the year ended December 31, 2023.&#8221; Please revise, here and on page 82, to reconcile these two statements, including whether a &#8220;disproportionate loss&#8221; across accounts would result in a similar loss to your revenue, and note whether any customer accounted for more than 10% of your revenue during the year ended December 31, 2024. Please also revise your disclosures on page 82 to clarify the difference, if any, between your installed base of accounts and customers.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 23 and 84.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Our Heartflow Platform and the data and models it generates could have bugs, defects or errors, including human quality control errors&#8230;, page&#160;25</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;you&#93; have in the past, and may in the future, experience defects or errors in &#91;y&#93;our Heartflow Platform or the data and models it generates that remain undetected by &#91;y&#93;our analyst-based review process.&#8221; Please revise to briefly discuss, if material, these prior defects or errors in the Heartflow Platform or the data and models it generates, including any related negative impacts on your business or operations. We also note your disclosure on page 39 that &#8220;&#91;yo&#93;ur products have been in the past, and may in the future, be the subject of medical device reports of adverse events with the FDA&#8217;s Manufacturer and User Facility Device Experience database, including reports of false negative results and incorrect or imprecise results or readings.&#8221; Please </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">revise to briefly discuss these past medical device reports of adverse events, if material, including any reports of false negative results and incorrect or imprecise results or readings, and the related impact on your business or operations.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 28 and 41.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Off-label or other unlawful promotions of our products could result in costly investigations and sanctions from the FDA and other&#8230;, page&#160;39</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure here and throughout the filing that the Heartflow Platform has been &#8220;cleared by the FDA, and the equivalent regulatory authorities in Israel, Saudi Arabia, United Arab Emirates, licensed in Bahrain, CE Marked in the European Economic Area, the United Kingdom and Australia, received medical device licensing in Canada and been approved for marketing authorization in Japan by the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;), all for specific indications for use.&#8221; We also note your disclosure on page 125 that &#8220;&#91;o&#93;nly the FFRCT Analyses is authorized for clinical use in the European Economic Area, United Kingdom, Australia, Canada, and Japan,&#8221; and that the &#8220;Heartflow Platform is regulated in the United States by the FDA as a Class II medical device.&#8221; Here and in your prospectus summary, please revise to note, as you do on page 25, the specific FDA authorization received by your Heartflow Platform and each of the products within your Heartflow Platform. Please also revise your disclosure on page 39 to clarify that only the FFRCT, and not your Heartflow Platform, is authorized for clinical use in the EEA, the UK, Australia, Canada, and Japan. Please also briefly discuss, or cross-reference to your disclosures elsewhere, the significance of CE Mark, PMDA, and medical device licensing approval outside of the United States. Finally, we note your disclosure on page 36 that you &#8220;currently have ongoing responsibilities under U.S., U.K., European Economic Area, Switzerland, Canada, Australia, Japan, Saudi Arabia, United Arab Emirates, Bahrain and Israel (registered or licensed regions) regulations.&#8221; Please revise to clarify the nature of the ongoing responsibilities, including whether each of your products is authorized for clinical use in each of these listed jurisdictions.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 6, 38, 42 and 110.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Market and Industry Data, page 70</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;t&#93;his prospectus contains estimates, projections, and other information concerning our industry and our business, as well as data regarding market research, estimates, and forecasts prepared by our management or third parties, including but not limited to, Clarivate.&#8221; Please revise your disclosure throughout to cite to specific sources prepared by third parties, where appropriate. In addition, please tell us whether you commissioned any industry or market data that you reference in the prospectus, including from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Clarivate. If so, file consents of the relevant third parties pursuant to Rule 436 of the Securities Act as exhibits to your registration statement.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 1-4, 6, 98, 99, 102, 104, 108, 109 and 126. In addition, the Company advises the Staff that it has not commissioned any of the third-party data included in the Draft Registration Statement.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds, page&#160;71</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;you&#93; expect to use the remainder of the net proceeds from this offering, together with &#91;y&#93;our existing cash and cash equivalents, to fund &#91;y&#93;our sales and marketing efforts, fund research and product development activities and for other general corporate purposes, including working capital, operating expenses, and capital expenditures.&#8221; Please revise to briefly discuss these planned research and product development activities, including the specific product(s) for which you intend to use these proceeds. Refer to Item 504 of Regulation S-K.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page 72.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations Components of our results of operations, page 82</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that key factors that drive your revenue include expanding the adoption of the Heartflow Platform in new accounts and expanding the utilization of your system in existing accounts. To provide context to investors for your statements about your growth potential, please revise to clarify the amount or percentage of your revenue cases attributable to existing compared to new accounts for the relevant financial quarters presented on page 82. As a related matter, please clarify how you determine whether an account is &#8220;active.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page 84.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Results of Operations, page&#160;84</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that your increase in revenue was primarily attributable to an increase in volume, partially offset by a modest reduction in average sales price. Please clarify the reason for this reduction, and disclose whether you expect this trend to continue in future financial periods.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page 86.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contractual Obligations and Commitments, page 90</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;you&#93; entered into various exclusive technology licensing agreements that require &#91;you&#93; to make annual royalty payments in fixed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">amounts as well as certain milestone and revenue-based payments.&#8221; In an appropriate place in your filing, please disclose the material terms of these licensing agreements and file the agreements as exhibits to your registration statement, or provide your analysis as to why these agreements are not required to be filed. Refer to Item 601(b)(10) of Regulation S-K.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company acknowledges the Staff&#8217;s comment and respectfully advises the Staff that it does not believe the exclusive technology licensing agreements are material contracts under Item 601(b)(10) of Regulation S-K. Item 601(b)(10)(ii) of Regulation S-K states&#58; &#8220;&#91;I&#93;f the contract is such as ordinarily accompanies the kind of business conducted by the registrant and its subsidiaries, it will be deemed to have been made in the ordinary course of business and need not be filed unless it falls within one or more of the following categories, in which case it shall be filed except where immaterial in amount or significance.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contracts Not Made Outside the Ordinary Course of Business</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company respectfully advises the Staff that technology licensing agreements are commonly entered into by companies in the Company&#8217;s industry. The Company has previously entered into, and may in the future enter into additional technology license agreements when the Company believes doing so would be beneficial to its business and as such does not consider the exclusive technology license agreements referred to in the Draft Registration Statement to be contracts entered into outside the ordinary course of business. </font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Business is Not Substantially Dependent on the Licensing Agreements</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsection (B) of Item 601(b)(10)(ii) states that a contract entered into in the ordinary course of business would be a &#8220;material contract&#8221; if such contract is a &#8220;contract upon which the registrant&#8217;s business is substantially dependent, as in the case of continuing contracts to sell the major part of registrant&#8217;s products or services or to purchase the major part of registrant&#8217;s requirements of goods, services or raw materials or any franchise or license or other agreement to use a patent, formula, trade secret, process or trade name upon which registrant&#8217;s business depends to a material extent.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company respectfully advises the Staff that the Company&#8217;s business is not substantially dependent on the exclusive technology licensing agreements. As described in the Draft Registration Statement, the Company&#8217;s owned and licensed patent portfolio includes approximately 586 issued patents and 103 pending patent applications globally, and the exclusive technology licensing agreements collectively constitute an insignificant portion of the Company&#8217;s patent portfolio. In addition, the Company&#8217;s owned patent portfolio includes patents with claims that overlap with other owned patents in its portfolio as well as those patents that are the subject of the exclusive technology licensing agreements. The Company further advises the Staff that the payments made under these exclusive technology licensing agreements are not material to the Company, and the aggregate of such payments during 2024 was less than $5 million. The Company does not expect future licensing fees or milestone or revenue-based payments, if any, to be material to the Company. As such, the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">respectfully submits that the Company and its business are not substantially dependent on the exclusive technology licensing agreements and that filing such agreements as material contracts would not enable investors to form a more informed view of the Company&#8217;s business as a whole.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Our Success Factors, page 97</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;y&#93;our proprietary database of more than 100 million annotated CCTA images, growing daily, has fueled ongoing AI-driven algorithm refinement for over a decade&#8212;enhancing &#91;y&#93;our platform&#8217;s value for patients, physicians, and payors.&#8221; Please revise to provide additional detail regarding the development of your proprietary database, including your source(s) for the more than 100 million annotated CCTA images. </font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 2, 99 and 101.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that utilization rates for Heartflow FFRCT Analysis typically scale rapidly after onboarding, approaching approximately 33% of eligible CCTA tests within an account. Please clarify how you calculate utilization rates, including the period by which you measure these rates, and provide additional detail describing the significance of utilization rates to your business and operations, including how these rates translate into increasing Heartflow revenue cases. </font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 86 and 102.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Our Clinical Results and Economic Evidence, page 114</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure that &#8220;&#91;t&#93;he accuracy, clinical utility and economic benefits of &#91;y&#93;our Heartflow Platform have been evaluated in over 100 clinical studies and more than 130,000 patients, including two large randomized controlled trials, with results published in over 600 peer-reviewed clinical publications.&#8221; We also note your disclosure beginning on page 144 detailing some but not all of the trials, studies, and research you reference throughout your filing. Where you reference certain trials, studies, or research supporting your disclosure, please identify the specific source to which you refer. In addition, please revise to discuss your material clinical studies, trials and any other research cited in further detail. In particular, please disclose the date(s) and location(s) of the studies and trials&#59; the sponsor(s)&#59; the number of participants, including how participants were selected&#59; the results of the studies and trials, including how results were measured&#59; key assumptions&#59; any serious adverse events&#59; and whether statistical significance was demonstrated, including supporting p-values, as appropriate. Please also disclose whether any of the parties involved, including the sponsors in the studies and trials, are affiliates or partners of Heartflow. As an example only, we note that you have included references to certain studies which are not discussed in detail in the registration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">statement, such as the SCOT-HEART randomized controlled trial and the FAME 1 and FAME 2 RCTs.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 119-125.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property, page&#160;122</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure on page 123 that &#8220;&#91;a&#93;ssuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable, &#91;y&#93;our owned and licensed issued U.S. patents expire between 2018 and 2041.&#8221; Please revise to clarify which of your patents have expired, and disclose which of your patents will expire in the near-term.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page 129. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Relationships and Related-Party Transactions, page 155</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please revise to clarify the relationship between Hayfin Services, LLP and Hayfin HeartFlow UK Limited.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 161, 163-165 and 169.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please revise to disclose the related parties, including your directors and officers and holders of more than 5% of your capital stock and affiliates, that are parties to the investor rights agreement, the voting agreement, the right of first refusal and co-sale agreement and the management rights letters. Refer to Item 404 of Regulation S-K. We also note your disclosure on page 159 that &#8220;&#91;c&#93;ertain of &#91;y&#93;our obligations under the BCLS Letter Agreement will remain in effect after the completion of this offering, including certain indemnification obligations.&#8221; Please revise to discuss the obligations that will remain in effect.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 164 and 165.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note your disclosure on page 160 that &#8220;&#91;you&#93; have entered into change in control and severance agreements with &#91;y&#93;our executive officers that, among other things, provide for certain compensatory and change-in-control benefits, as well as severance benefits.&#8221; Please revise to disclose the material terms of these agreements and file the agreements as exhibits to your registration statement. Refer to Item 601(b)(10) of Regulation S-K. We also note your disclosure that &#8220;&#91;you&#93; have entered into indemnification agreements with certain of &#91;y&#93;our current directors and executive officers and intend to enter into new indemnification agreements with each of &#91;y&#93;our current directors and executive officers before the completion of this offering.&#8221; Please file the form of indemnification agreement as an exhibit to your registration statement.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company respectfully acknowledges the Staff&#8217;s comment and advises the Staff that the Company expects to enter into a severance plan covering its executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">officers and indemnification agreements with its directors and executive officers&#59; however, the terms of the proposed severance plan and indemnification agreements have not yet been finalized. Once the terms of the severance plan and indemnification agreements have been finalized, the Company will revise the applicable disclosure to describe the material terms thereof and file the applicable plan or agreement.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2. Summary of Significant Accounting Policies</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition, page F-12</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please expand your disclosures to address the following&#58;</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Provide the payment terms disclosures required by ASC 606-10-50-12.b.</font></div><div style="margin-bottom:9pt;padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Address whether you have needed to make any material adjustments to the variable consideration estimates.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page F-13. The Company respectfully advises the Staff that there have been no material adjustments to variable consideration estimates.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7. Commitments and Contingencies, page F-22</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please provide the disclosures required by ASC 450-20-50 for legal proceedings and&#47;or litigation. In this regard, we note the disclosures provided on page 137.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on page F-24.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">30.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We note that you make various statements throughout the registration statement regarding your leadership in your field and the efficacy of your products including, but not limited to, the following&#58;</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 1&#58; CCTA has become the &#8220;preferred&#8221; first-line test for patients with suspected CAD. </font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 2&#58; Improved workflow through your Heartflow RoadMap Analysis &#8220;reduces CCTA interpretation times by approximately 25% and reduces variability between reviewing physicians by approximately 50%,&#8221; which leads to &#8220;more consistent diagnoses and standardized patient care.&#8221; </font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 3&#58; You believe your platform is the &#8220;most extensively studied AI-enabled test for CAD,&#8221; and &#8220;&#91;i&#93;ts accuracy, clinical utility and economic benefits have been evaluated in over 100 clinical studies and more than 130,000 patients, including two large randomized controlled trials, with results published in over 600 peer-reviewed clinical publications.&#8221; </font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 4&#58; &#8220;CCTA has been clinically demonstrated to have the highest diagnostic performance of all traditional non-invasive imaging test for CAC&#8221; and &#8220;superior diagnostic accuracy.&#8221;</font></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 7&#58; Your Heartflow FFRCT Analysis has &#8220;the highest diagnostic accuracy for a non-invasive CAD test and has demonstrated a high level of concordance to invasive fractional flow reserve ('FFR').&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 7&#58; &#8220;The Heartflow Plaque Analysis has been validated against the reference standard of invasive intravascular ultrasound (&#8220;IVUS&#8221;) and shown to have a 95% agreement with IVUS in quantifying total coronary plaque volume.&#8221; </font></div><div style="margin-bottom:9pt;padding-left:86.9pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Page 106&#58; You estimate that &#8220;there are approximately 200 million patients globally with a high risk of cardiovascular events, of which 71 million live in the United States. In the future, we believe certain sub-segments of this population may be appropriate candidates for our platform.&#8221; </font></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please revise your disclosure throughout the registration statement to provide the basis for any statements, including those above, related to leadership in your field and the efficacy of your products. Please also ensure you disclose any relevant metrics or material assumptions upon which these statements are based, and include cross-references to any clinical studies, trials, or research supporting these statements.</font></div><div style="margin-bottom:9pt;padding-left:40.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the Staff&#8217;s comment, the Company has revised the disclosure on pages 1-3, 5, 7-9, 98-100, 103, 108, 111, 113, 114, 116, 117 and 119-125.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;text-indent:-35.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;letter-spacing:-0.004em;line-height:120%">31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Please provide us with supplemental copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, have presented or expect to present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not you retained, or intend to retain, copies of those communications.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Response</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; The Company respectfully advises the Staff that, under separate cover, it will herewith supplementally provide the Staff with copies of the written materials that have been presented visually, but not distributed, to potential investors in &#8220;testing-the-waters&#8221; meetings in reliance on Section 5(d) of the Securities Act of 1933, as amended. The Company respectfully requests that the Staff destroy such materials upon completion of its review. To the extent that any written communications may in the future be presented to additional potential investors, the Company will provide the Staff with copies of any such written communications.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We appreciate the Staff&#8217;s comments and request that the Staff contact the undersigned at (415)&#160;984-8943 or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">rcoombs&#64;omm.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with any questions or comments regarding this letter and&#47;or the Revised Registration Statement.</font></div><div style="margin-bottom:9pt;padding-left:280.8pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Ryan Coombs</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ryan Coombs</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">O&#8217;Melveny&#160;&#38; Myers LLP</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div style="text-align:right"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></td></tr></table></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">cc&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">John C.M. Farquhar, Chief Executive Officer, Heartflow, Inc.</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vikram Verghese, Chief Financial Officer, Heartflow, Inc.</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Angela Ahmad, Chief Legal and Compliance Officer, Heartflow, Inc.</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shelly Heyduk, O&#8217;Melveny &#38; Myers LLP</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dave Peinsipp, Cooley LLP</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kristin VanderPas, Cooley LLP</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Denny Won, Cooley LLP</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Charles S. Kim, Cooley LLP </font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
M_]C_X  02D9)1@ ! 0(!+@ [  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         "''0  &0
M -@%   9    1TE-4" R+C$P+C,X   R,#(U.C S.C$W(#$P.C(W.C P  $
M : #  $    !         /_A#,UH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](EA-4"!#;W)E(#0N-"XP+45X:78R(CX@/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(@>&UL;G,Z1TE-4#TB:'1T<#HO+W=W=RYG:6UP+F]R
M9R]X;7 O(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B('AM<$U-.D1O8W5M96YT240](F=I;7 Z9&]C:60Z9VEM<#HU93$R9C0Q
M9"UA,C=B+31A,64M.31A-"TX-#,W.3(W.68W.#$B('AM<$U-.DEN<W1A;F-E
M240](GAM<"YI:60Z-#,X,F9E.38M9#8Q,BTT9#,R+6%F8S(M9#=D93DQ86)A
M,3=E(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z86(Q,3,W
M-34M9&%E8RTT-CDS+3EC,C(M,#AF839A-S$P9# T(B!D8SI&;W)M870](FEM
M86=E+VIP96<B($=)35 Z05!)/2(R+C B($=)35 Z4&QA=&9O<FT](E=I;F1O
M=W,B($=)35 Z5&EM95-T86UP/2(Q-S0R,C(U,C(S.#8T,3<R(B!'24U0.E9E
M<G-I;VX](C(N,3 N,S@B('AM<#I#<F5A=&]R5&]O;#TB1TE-4" R+C$P(B!X
M;7 Z365T861A=&%$871E/2(R,#(U.C S.C$W5#$P.C(W.C P+3 U.C P(B!X
M;7 Z36]D:69Y1&%T93TB,C R-3HP,SHQ-U0Q,#HR-SHP,"TP-3HP,"(^(#QX
M;7!-33I(:7-T;W)Y/B \<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX]
M(G-A=F5D(B!S=$5V=#IC:&%N9V5D/2(O(B!S=$5V=#II;G-T86YC94E$/2)X
M;7 N:6ED.F,P9C$U8F9E+64R868M-#9E."UA839C+3$U-C5B.39C9#5D-"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB1VEM<" R+C$P("A7:6YD;W=S*2(@<W1%
M=G0Z=VAE;CTB,C R-2TP,RTQ-U0Q,#HR-SHP,R(O/B \+W)D9CI397$^(#PO
M>&UP34TZ2&ES=&]R>3X@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T
M(&5N9#TB=R(_/O_B K!)0T-?4%)/1DE,10 ! 0   J!L8VUS!$   &UN=')2
M1T(@6%E:( ?I  , $0 / !H %6%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
M 0    QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$( )@#  ,!$0 "$0$#
M$0'_Q  <  $  P$! 0$!            " D*!P8$!0+_Q  ; 0$  P$! 0$
M            !@<(!00# O_:  P# 0 "$ ,0   !O\  /SRH J!(0'YY[ G^
M7/%EX .)]_C5=6]6@FS )D(33^&@6=5)9'=X[W  !!&Q81#R<1("[&@KD
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M4MR5?5+<E7C4]CW3=7=O5I5+<E7@#0EF:^I11"3 "IJYZLJPN&L@!JTQOJ
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M^#\G[?(=!YGO_6^/U        C[)>#G-U'GT6<U)9%O=)6P
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M4)$S_P <L'1"WPE6.X+9/I5[<G-PA]7S(/\  @C[4-D' @C[(P@X.!30:/\
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M/B'&K, 6PR =?'.H=LULT 62=/4%:,7<Q<N+UM@X&/"IL$8UG#XBRJQ!EN,
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M@QHY1'@2JP ' F0DW&(@3,H_X7E(^AOM'\#U\&?NUIO\Y\?:Z>4/3^7;IZD
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M=3U.E1B"D;#P%N! !C7'UEDP)FX9+K@PQW@MY': ,I@9  4 +6 K6L1!:P&
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M,G8K0(=S,F0=O,O$$0H(\!3',Z 9KG)9D!2)A,@4C,@T"6P-XVG%BS)9C[#
MB$MQF8Z^$:$4-!I1L/,MCV]I 1E!S:B"3/CVQ(:L5UF(1 9@4QE,RP^G&?[R
MZE_)_ 5?0UZK%S1M3KRHGD5-YJ4&<F=A(2ZM@*_&9186N1"-\YC"1(2D9ZN!
M[@5->4#,8&ZAU.#-D+@#*0>OVQL9-97&N"]QDC<.,R40!==ZSV.E<N8<SLM6
MQ9Y>6',Y"C;AGB6.6..6);;[XS[.GZ2/^S?^1_\ 1Z?I(_[-_P"1_P#1Z</<
M6^?KK:?F_LO+JG9YG:N?O@U*L,.S)VWYV664_L[8]^\=-<^>M7^M-0^+;U:'
M\]:1]::?\6KT/*#ID)N5]46)8W1E-F<3D(L5Q"%$3)*0$G5]@!4"ONJ&R,R)
MDCU:CJKM0JZ3689$.FTRK[$M01G+V0,A*XR,8I+HIW9M.:3G:2(F-Z:=3/4+
MU2BO*"LO6J2!<ME8$4<QW+B8DA2O)I^(8@ *2(1B2A"5UDIKI'!*%+2H-R+%
M:A@ '(I(BQ$8C<IDI]LS,]7'U/GZ)%F!5E1M*:1E'K.2[>L:U%C,^-S:YF$D
M D*LIF2 !GJ\GFI"#+FE-9MSMK=0)Y8C+ '"T,%,PTVFJ$&*X@QA==S/!L6?
M7Q#K?F&DJYV;M7,M!6Y?.Y&V:G-SSY3M]N3CCC'[6^7=M/Z2/^S?^1_]'I^D
MC_LW_D?_ $>G#VM^?J3;G9NR\NT=;E\[G[X*2W//E)VWYV..,_L[Y=^T:Y\R
MZO\ 5>H?"-Z^#/WETW^<^ M>AY0_F6K]:)^$N]?DW^F?L[\=UZI07JFGVJ#9
MQ&RJ1@_%/+8,P:6XB:Y/E.$&89B+,<"\)3T,#49K8!+8LB!BS&0,#"<2 Q+8
MA(2B8(9B)B8VGOZH<P4LKP7J6M2XPV'Q,0+P466V48C9=&T3 EGN43(CCU:+
MIWFK2Z=#+,D*]:6^0RYIDY^$X+F50YAPK((+EXY[EO,]?&_#DI-VNU,>0P@F
M\C8 Y33D%185M PP7LD>?'>Z+!R[=@-/L_4!FHP8LR6Q9":V 4@8&$Y"8$.Q
M"0E$2)1,3$QO'?TT#CFO8@*NLR-6Q K ;O\ _/99)X>M$0QJ%C($1S/99V<<
ME5"%JD#!H Q9BQ;!$UL H,# XR$P(=Q(2&8D2B9B8G>.[_7\I'T-]H_@>O@S
M]VM-_G/C[75Q%IDZMI%NHL1FQC#JN0@4]H3,, 0)A *B>,%6YN8X XY+<,A+
MKTBA.IZG2HQ!2-AX"W @ QKCZRR8$S<,EUP88[P6\CM &4P,]7&?[RZE_)_
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MY4K(CD9K$1R(H&-Y[RF(COGT..JMJWI%==2L^TR-14<KKI8XX"*UL9.16)%
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M8P^0QLP$E:K&*>0V L;0>UJ,,E:GL5:!3"B!/= R) P9D"^3TUC8R^=QF/.
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MRI25("VY91543)F%BRPT5!)R(F4!!'$E(B4Q&N@S/H[5ZZ:E=%6N'&BLE5=
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ME23WGOL&(U/#O4RG+>H8A9ZA425NS /W#-BS.Q*WUQ] .KH7+5D<R<IO^J(
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M=+^_V_"+I_Y]PW\3I?W^W7%BO;ZHR=BJ]-E#/);'UV@Y)[<=4 MC%D0%M,2
MM)G0AD9],3X]V>?JT/A+&Y"XFHAG'>K'996KUX=&B+0R]IK,G.#RDK5ZX[*[
MCCCG=R?A%T_\^X;^)TO[_;\(NG_GW#?Q.E_?[=:Y<<QU#=>EO+5K;*-0O8R,
MIK:PPEFF2%R76BLO0TC(C2T/R1@5AX=#YK#U.E\97M9;&5GK\[O18OU4N#=D
M;9CO6QHF.X"$QUB-1*"CT3';\(NG_GW#?Q.E_?[?A%T_\^X;^)TO[_R.FNM<
MGT[MK_\ WL9'-/P>TX7L-NA;Z]GB:Q&C(WDK0ZY<CRX8>WG'&]==,Y*(TR 4
M6[#,D9+2G(0+./27F4TC,]18"U6F,E<ZR,2#8#Y&9Z]Z?Q*_960RMH@W*KX]
M@.7Z8;LEUL9*ND.1< R!)MI<,!L56!.O;J+JK)]1NGS3.*B#B;5QZ].%&HPL
M9,X$3LN@(GVSM=I,?Y<*ZFRJ/# Y[!IP>&4W-8E358G'+:IF1I@Q; II$P,"
M=! 8%$B0E$2,Q,3&O;\(NG_GW#?Q.E_?[9[/8-V#S*E9K$M:W$Y%:E+R-,V,
M8=-P@  +I(S,I@1$8F2F8B(U^3W<9VOB<I9J7&)KU<FD=;+C!0)L4X<Q/(YK
MEK6EBV6%SZK#.Q-81VC)S/X1=/\ S[AOXG2_O]OPBZ?^?<-_$Z7]_MUEU5BT
M]/W54+]"_:OA./%5:U7M<:[0&-AS038A@ %>&BMD0<#:.O!@0$7RNFN\*]AD
MHH7T_"&.3H"RWR-ZJG<N(!9E,K>E"X9P5FPLM2!46TUU L<1U/@\V*O(WT\[
M?1%)Y"B]!BF',#RQS!MX@F=[:_-7U!FQQPLICQ8Q:5FUI@I2@)C6L* 6M81)
M&9F4P(  Q)$13$#$3,SIVSG>/AJ"7+Q9_"E^.5:]@,BBIRR$(-[RXN=,ZD:_
M)2X;$*V\Z!8#^V2RE_,6IN9*R=JQ( O>4 $"L/R06I0@I0:R12*P&"89L*)8
MPR+M@6+3G,,UI@I2LMCF-:PH!:UA<21F9E,"  ,21$4Q Q$S,Z=OPBZ?^?<-
M_$Z7]_M^$73_ ,^X;^)TO[_;KC-8>WTODZ]7+8RR]GDMB*]^JYQ[<C4,MBUM
M(RV@)&6D3H(R4^B)^1W;7:='.6FW;=:FHL2]8MM/5763)N42@(-I ,G(@10,
M3K,"4Z:1/;\(NG_GW#?Q.E_?[?A%T_\ /N&_B=+^_P!N\_(X^_\  ?D+U.[Q
M?"7+Y2TBSQ[_ (/V<G"9[-^P]N[3=M+37;/R<+YCX'Q/F^;S7P91\SYC?YCS
M'E5<W/R>TYN3=R\GK[]V[UM?#*WUXK&WLBW9(TZS7P!MA,-8 SQ(AI04"=AN
MQ"_5.98P1$#*8&;%AUNP^U8/D?9<VP\]HCO<XR8P]H0(#N,IG: B,:Z#$1Z/
M]'']0YS%\44,I<0M')Q5^8FU!Y=^_P#$W<E6=289^LF=&SRQHR(*/C ZN^=O
MJ&,^Y=OC ZN^=OJ&,^Y=LAU#G,IRQ?REQZW\?+7YB54+BV;/Q-/'5C0E@?JI
MC5L<LZLF2G_H%3(Y"AR>0O7*7+MY?*6GUN39NV<G"8;]F\]N[7;N+33=/;\(
MNH/GW,_Q.[_?[?A%U!\^YG^)W?[_ &MY'(7^/S]ZY=XMW%YNT^SQ[]N_CYC/
M9OV!NVZ;MHZZ[8_V]?-9BHD*]7+9.LA>[8BO?M)2&XI,MBUM$!W&1&6D1J12
M4^F9[?A%U!\^YG^)W?[_ &_"+J#Y]S/\3N_W^UBQ8MN.Q:>ZR]FW>^PTW./:
M, .]C"(RV@(@.LSH(P,>B(_V726$^'\Y5IG&M56MN_Z=/Q1!#O7Z&I9^,,-5
M7<DI:KGYX&147CWIY>%U:>$41PVP<7[6TV!'E5<BJZF#LXW@^QO;$<GL640,
MEZFHQ_\ S6.[L//X^C?^'.+SM.K;XO@W?Q^90#N/?\(!OV;]N[8.[37:.NG;
MXI?^X/\ Q7_LNV!Z>QO3M4JV/ ]6GO?9?(G:L3&[CAK !8[$B4@I8 "PU,]O
M*US&>'4^7+-YR_>Y>5',2*4QS"$44%(5MBW3)JY0CS#0T"/,.<?&N3D8_P#S
M..J>?R%&AR<7G;E6IR[=_'YEX)Y-FX-^S?NV[QW::;AUU^3W@]55Z%&S@ZK.
M3)7D\5C9L(:51T1RP_<)QS6T22EIB!:"6^:DU?BW/_\ FNE<I3PN;JY2[YDE
M50L2*ZJE-8UCJ[*T#/+8K"L(%Q,DXEDZ@*^/1DL77[Q>E')!C+SJAENUKV*5
MLG+T*1C?-55E$[HB#'8\_5*-VT]P#\8'2/SM]0R?W+M\8'2/SM]0R?W+MFN]
M%[UL1@ZATIDU2&0M2EK^.(@FC%+8ZNLR9[.#-]F.'=,+!K!)#&,<PVM,VM:9
M,:UA2;&,.9(S,RF2,S*9(B*9DIF9F=?E?__$ $$0  (" 0," P(*" 4$ P$
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M<:AK5173:_T_A5.!K(I=W:0H+.4$/C-ST5),@VN#HS YSN'&1S^ZM*?R-O\
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MLWI9)ZIPV/7)DO7@@;DS7@ 2XR%1IC1DJCQHZEHCQT+!*$(2&%J2E2\""E*
M1!:P'  &,".,8Q^QD_XF45;MU-1=MG491!=DKC3@#VQRY$2-$?W%A1=8KLV+
M60QCZ<18]_(D)K:I,3RT9J4YWIL2MU! ]5F]MWG#13&]AJ#Y/B/*8SDI)4]7
MR=!S W[X6V6*3'Q15I-ZPHFG\34)V+QLE6%C-1+;R8'E+E560AV&9+#AZJ$"
M8W)^-'HB*Y6AJ"LFD.]8=(M9)"RFMZM(!SPPHCW;,9Y&;.-0FT@ O&B/I)^
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M&@:RZ=#$ASG'CWG^I=/?E/CWG^I=/?E/B?6ZAN/4(2=/RIJD^GU<3;*78U2
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M/B.]:1)N8MSCD8E3-DG4_P#!?N]4^Q9V\D6G&JJ^992 1@">:(,=DEHI%AJ
MFD"BPO!L6&3Z8(QQ\+$RRFMYIMA*D39;MBU\LJ6TWO;QJ$%!O:9%L4 +'KT
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M/2>&*<EJ\B:FJ,1-; +!@>,$.<9QX7!NYM>C5<5N8I1N0([[I 1^<+.+$(5
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M$^5FSK<!"[&+V-G\K!$)6,Y446O:QU6+$9XB9!;C"T$)(5Y76IWJZJJXH5D
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MJ7)G*/G&RG<VKN>W&PH:MF(=*)TGI*C1[3:7:,*  2A!(.D*&ZB?$$J4"#K
MANHKQA%@PC81N@:\2*+!A QE,T#6P ":PB,R5?WH4*0$2+6&WN9,*Z/KE.&$
M6#"-@&^!KU<HJ>,L_P#)4)!\3H?%4N1.P?RTBTP"((QH-UG +"<<7Z<WI$!C
MKA%3QEG_ )*AXU6L;\PUG1H%%@PB8J9H&MC3;2$4JI*,I>J#*$%]RMZ)8Y%%
M@P@8J9H&MC3;2$4JI*,H*8=L:IZ$\D(3<4!?J"$3OM5#9R/"4W3(X_L!8&34
M38EMTF8BQJ !5@A3<+'FB P664" )8S*(%U()I.IE>EK  H>$==J9!GC0/9
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M!\;X,L=('JH 6@<@T>Z^(-;%J@FYG$@Y UN6J";F=2[]4.PL">@[X\G>'^=
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M<                         "0 0 8"  (  #        00
M           #F      0#@ 4  4        00                      -
MP     0 #   @ $        00                      2D   " 0    !
M  4   ;:3,@00 ' !  +N2<  3:0Q$" "@7@      "&8 ""@#@< !@  "@0
M3(! # !T  #" '@ <, @ @1 @          @$!"@   8' 800,"@>!["8< B
M !DH!$  # B@           H("A  >  ! 000,#X4#D!@ @6 >@( # 84#BA
M      "    (4  @ 0"R2  00# $4!0 R1@" 8 0 "@($#ACH          $
M T4  $     00" 7< $    "   0 #(4X4A@$          "AL(   "@  80
M0#(-@   @  2   0  $! 8#$'@   0      @@$  4#@! (00 ,"AX # # :
M   0   B 0 < L@  0     !@"@    TX 800 , #@)!$(@"   0  !  @ &
M "G#*       8!   #D  !(00 # ! !@   B   0  "     !@ =     :2
M:2 *0  @ ' &$  2,     IBR( .3  (/    0"                *1
M        "3        # <
M     #"@(                                            ( "
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M2H5=Y#AH\\[=:LCQD0JN$2HBLH\$"5G;:/*Z"0'6JE=$@XDX%!6]4'@GM@"
ME(5AQV="D*$I[LJ<ZJ5TD'$G H+E2O@KI8U<EW)P#=UE^GL=)0%I!-BI7[,8
M1#_@1FU.2X*.EX)Z?C"GGTTL'IKDTWVE^2Q7H>'DBI_8_@!%HHO#R14_H?P
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MKU<Q9C<DEV8C"YL+(-"A<O#7N36Y&:Z0$]GX'NE'R=(@I 9K!2/0N$'R-^P
MVCC/6[.>V_*)XVIN[5D8 J,LA_MV[;NU9&(*C#(?R5FTB>U=1:E'DQY,]:T
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MQ5-7!(Q=%A&8N',G+Z&/"\\/'2Z($FIVQ<0K J9U(IG&C1>R/+ I@+8SW]X
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M[C2\#?M #"(RK7& -^T ((C*M=RH\C*?Y%SHP8:@-><R"NKXUW0MO(7KHU>
M-<Q-HXQ%Q\'NM #"(RK77!-PR,_-G%\VFBB%P]9K,2B0.^T ,(C*M<8,"%>"
M=+3WVZ-^7!=(K(H48,7)$0 HI47'QF(L4,3Z5A^/<D:KJWTE[>;]>V@2,$1'
MD$';0)&"(CPQ @ %%&#!B!  **$*\%Z6GOMF#%AWTO2T]]M](0@N/DX#LN!L
M<,+*BN2(A"(2R;%*2WL5".D^]UTIIC$PM'<P0$ 1"5+$^MMQ-^-XJ =U));V
>_M94 (3?*]:VWZ8(,&*34?)'K@T#W6@!A$95KO_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
